Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.04
-2.3%
$4.46
$3.42
$8.14
$283.32M1.941.63 million shs599,726 shs
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$0.27
+8.8%
$0.29
$0.20
$1.48
$69.97M2.861.83 million shs2.92 million shs
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$1.43
+1.4%
$1.41
$1.03
$2.57
$285.71M1.221.52 million shs1.18 million shs
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$3.03
-8.5%
$3.26
$1.42
$4.66
$269.68M0.79915,739 shs2.01 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-2.33%+9.80%+18.59%-23.87%-28.00%
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
+8.80%-9.33%+16.29%-52.82%-76.35%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
+1.42%+2.88%+3.62%-37.00%-25.13%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-8.46%-4.11%+0.66%-15.60%+302,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.4136 of 5 stars
0.02.00.00.02.40.80.6
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
2.6099 of 5 stars
4.24.00.00.01.70.80.0
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
2.6384 of 5 stars
3.51.00.00.02.72.51.3
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
2.7353 of 5 stars
3.61.00.00.03.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
2.43
Hold$1.52458.21% Upside
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
3.00
Buy$10.50634.27% Upside
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.14
Buy$18.60513.86% Upside

Current Analyst Ratings Breakdown

Latest ADAP, ATYR, ATAI, and ACB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.50 ➝ $1.00
5/14/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$1.00 ➝ $0.46
4/11/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/1/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.50 ➝ $3.00
3/26/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$3.00 ➝ $1.75
3/21/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.50
3/21/2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$3.15 ➝ $1.40
3/19/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/14/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
2/18/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/18/2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$16.00
(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.88$0.19 per share26.35$8.18 per share0.62
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.39N/AN/A$0.17 per share1.60
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$308K927.62N/AN/A$1.47 per share0.97
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
$235K1,147.58N/AN/A$1.54 per share1.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05100.8211.45N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$113.87M-$0.27N/AN/AN/A-25.43%-74.15%-15.09%N/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$40.22M-$0.93N/AN/AN/AN/A-65.75%-52.71%N/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%N/A

Latest ADAP, ATYR, ATAI, and ACB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/13/2025Q1 2025
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$0.18-$0.18N/A-$0.18$6.55 million$7.29 million
5/7/2025Q1 2025
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.19-$0.17+$0.02-$0.17N/AN/A
3/24/2025Q4 2024
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
-$0.17-$0.26-$0.09-$0.29$16.56 million$3.22 million
3/17/2025Q4 2024
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million
3/13/2025Q4 2024
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
N/AN/AN/AN/AN/A
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
0.62
3.85
3.82
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.14
5.81
5.81
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
0.02
5.41
5.41

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
31.37%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
28.41%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
61.72%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
12.74%
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
31.20%
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Adaptimmune Therapeutics plc stock logo
ADAP
Adaptimmune Therapeutics
490257.23 million224.05 millionOptionable
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
80199.80 million115.45 millionOptionable
Atyr PHARMA INC stock logo
ATYR
Atyr PHARMA
5389.00 million80.84 millionOptionable

Recent News About These Companies

Brokers Offer Predictions for Atyr PHARMA Q2 Earnings
Atyr PHARMA INC stock logo
Leerink Partnrs Estimates Atyr PHARMA Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.04 -0.12 (-2.33%)
As of 05/14/2025 04:00 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 +0.02 (+8.80%)
As of 05/14/2025 04:00 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Atai Life Sciences stock logo

Atai Life Sciences NASDAQ:ATAI

$1.43 +0.02 (+1.42%)
As of 05/14/2025 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atyr PHARMA stock logo

Atyr PHARMA NASDAQ:ATYR

$3.03 -0.28 (-8.46%)
As of 05/14/2025 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.